Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
74 studies found for:    vaccine adverse reactions | Open Studies
Show Display Options
RSS Create an RSS feed from your search for:
vaccine adverse reactions | Open Studies
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting A Clinical Trial for Inactivated Japanese Encephalitis Vaccine in Healthy Chinese Infants
Condition: Encephalitis
Interventions: Biological: 0.5ml experimental vaccine on day 0,7 Vero cell-derived inactivated Japanese Encephalitis vaccine;   Biological: 0.5ml experimental vaccine on day 0,28 Vero cell-derived inactivated Japanese Encephalitis vaccine;   Biological: 0.5ml active comparator vaccine on day 0,7 inactivated freeze-dried Japanese Encephalitis vaccine(Vero cell)
2 Not yet recruiting A Phase I Clinical Trial for Inactivated Quadrivalent Influenza Vaccine (Split Virion) in Healthy Adults in China
Condition: Influenza
Intervention: Biological: inactivated quadrivalent influenza vaccine (split virion)
3 Not yet recruiting Hepatitis B Vaccination in Infants
Conditions: Meningococcal Disease;   Pneumococcal Disease;   Haemophilus Influenzae Serotype b Disease;   Diphtheria, Tetanus and Pertussis;   Hepatitis b
Interventions: Biological: Menjugate;   Biological: Menitorix;   Biological: NeisVac-C
4 Not yet recruiting The Safety Research of Freeze-dried Rabies Vaccine(MRC-5 Cell) in Chinese Humans
Conditions: Rabies;   Healthy
Interventions: Biological: 2.5IU/ml in rabies vaccine (MRC-5 Cell) humans aged 10-20 years old;   Biological: 2.5IU/ml rabies vaccine (MRC-5 Cell) in humans aged 21-60 years old;   Biological: 2.5IU/ml rabies vaccine (MRC-5 Cell) in humans(from 10-20 years old);   Biological: 2.5IU/ml rabies vaccine (MRC-5 Cell) in humans(from 21-60 years old)
5 Not yet recruiting Prospective Cohort Study to Evaluate Safety/Immunogenicity of Butantan Influenza Vaccine in Healthy Adults/Elderly
Condition: Influenza
Intervention: Biological: Butantan Fragmented Inactivated Trivalent Influenza Vaccine
6 Recruiting Immunogenicity and Safety of Meningococcal (A, C, Y and W135) Conjugate Vaccine
Condition: Meningitis
Interventions: Biological: MCV-ACYW135 Vaccine Group;   Biological: MPV-ACYW135 Vaccine Group;   Biological: MPV-A Vaccine Group;   Biological: MCV-AC Vaccine Group;   Biological: Hib Vaccine Group
7 Recruiting A Clinical Trial on the Candidate Vaccine cAd3-EBOZ in Healthy Adults in Switzerland
Condition: Ebola Vaccines
Intervention: Biological: cAd3-EBOZ
8 Recruiting Safety & Immunogenicity of MMR Vaccine by DSJI to That by Needle-Syringe in 15-18 Months Old Children
Condition: Immune Response to MMR Vaccine
Intervention: Biological: MMR vaccine
9 Recruiting Immunogenicity and Safety of Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine
Condition: Meningitis
Interventions: Biological: Minhai Bio;   Biological: Hualan Bio
10 Recruiting VZV Vaccine for Hematopoietic Stem Cell Transplantation
Condition: Varicella Zoster Infection
Interventions: Biological: Zostavax;   Biological: Normal Saline
11 Unknown  Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients
Conditions: High Risk HLA-A2+ Melanoma;   Metastatic Disease
Intervention: Biological: Melanoma vaccine modified to express HLA A2/4-1BB ligand
12 Recruiting The Safety and Immunogenicity Research of Live Attenuated Varicella Vaccine After the 2 Doses Vaccination
Condition: Varicella
Interventions: Biological: HBV-3;   Biological: HBV-6;   Biological: varicella-3;   Biological: varicella-6
13 Unknown  Safety and Immune Response to Adjuvanted A(H1N1)v Influenza Vaccine in HIV-1 Infected and Immunosuppressed Adult Patients
Conditions: HIV-1 Infection;   Cancer;   Immunosuppression
Intervention: Other: serologic testing
14 Unknown  Assessment of Needle-free Disposable-syringe Jet Injector (DSJI) ID Dose-sparing of Pandemic A H1N1 Influenza Vaccine
Condition: Influenza
Intervention: Biological: 2012 trivalent influenza vaccine
15 Recruiting Safety and Efficacy of Intradermal Trivalent Influenza Vaccination in Institutionalized Older Adults
Condition: Influenza, Human
Interventions: Drug: Intanza;   Drug: Vaxigrip
16 Recruiting Immunogenicity and Reactogenicity of a Trivalent MMR (Trivivac) in Healthy Infants
Conditions: Immunogenicity;   Reactogenicity
Intervention: Biological: Trivivac vaccine
17 Not yet recruiting Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of an Adenovirus-based Tuberculosis Vaccine Administered by Aerosol
Condition: Tuberculosis
Intervention: Biological: Ad5Ag85A
18 Unknown  Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine,Formulation 2011-2012, in Dialysis Patients
Condition: Influenza
Intervention: Drug: AdimFlu-S
19 Recruiting Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination
Conditions: Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Chronic Myeloid Leukemia;   Non Hodgkin's Lymphoma;   Hodgkin's Disease;   Myelodysplastic Syndrome;   Multiple Myeloma;   Aplastic Anemia
Intervention: Biological: allogeneic donor derived B-lymphocytes
20 Recruiting αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies
Conditions: Malignant Neoplasm of Pancreas Metastatic to Peritoneal Surface;   Malignant Peritoneal Mesothelioma;   Peritoneal Carcinomatosis
Interventions: Biological: DC vaccine;   Drug: Celecoxib;   Drug: Interferon Alfa-2b;   Biological: rintatolimod

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years